Printer Friendly

MICROPROBE RECEIVES TWO U.S. PATENTS FOR NOVEL DNA PROBE REAGENTS; ALLOWS ROOM-TEMPERATURE EXTRACTION AND HYBRIDIZATION

MICROPROBE RECEIVES TWO U.S. PATENTS FOR NOVEL DNA PROBE REAGENTS; ALLOWS
 ROOM-TEMPERATURE EXTRACTION AND HYBRIDIZATION
 GARDEN GROVE, Calif., June 15 /PRNewswire/ -- MicroProbe Corp., based here, today announced the issuance of two U.S. patents: Number 5,124,444 claiming the use of lactams in methods that promote nucleic acid extraction, and Number 5,105,730 claiming the use of lactams in the hybridization of nucleic acids in diagnostic applications of DNA probes. Both patents enjoy the advantages of lactams (or pyrrolidones), which are a class of laboratory reagents that remain chemically stable at room temperature and are ideal for promoting the extraction and hybridization of nucleic acids, either in the form of DNA or RNA.
 "Lactams avoid the problems encountered with toxic organic solvents, such as phenol and chloroform, and appear to be an excellent alternative to using formamide which has a number of disadvantages, notably instability," explained Michael Gendreau, M.D., Ph.D., vice president of research and development for MicroProbe's diagnostics division. Extraction and hybridization are required steps in the methodology used to identify the presence of target nucleic acid in complex biological samples. Hybridization refers to the natural binding that occurs between two complementary strands of DNA or RNA.
 U.S. Patent 5,124,444 is entitled, "Lactam-containing Compositions and Methods Useful for the Extraction of Nucleic Acids." U.S. Patent 5,105,730 is entitled, "Lactam-containing Compositions and Methods Useful for theHybridization of Nucleic Acids."
 Founded in 1985, MicroProbe Corp. is commercializing synthetic DNA probes for the rapid detection and identification of multiple pathogens, and the treatment of certain infectious diseases and cancers. The privately held company operates three divisions -- a diagnostics and a therapeutics division located together in Bothell, Wash., and an OEM systems division operating as Source Scientific Systems in Garden Grove.
 -0- 06/15/92
 CONTACT: Harvey Hoyt, M.D., of MicroProbe, 206-485-8566; or Charles Versaggi of Versaggi & Associates, 408-358-4162, for MicroProbe CO: MICROPROBE CORP. IN: MTC ST: CA -- SJ003 -- X352 06/15/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1992
Words:332
Previous Article:HUGHES AND ICL TEAM TO BRING DEFENSE SECURITY TECHNOLOGY TO COMMERCIAL MARKET
Next Article:RAYNET'S 'RIDES' OS SOFTWARE NOW TO SUPPORT FIVE SUPPLIERS FOR FIBER IN THE LOOP; THREE MORE SUPPLIERS SIGN WITH RIDES BUSINESS UNIT
Topics:


Related Articles
MICROPROBE AND OLYMPUS TO DEVELOP DNA PROBE-BASED DIAGNOSTIC SYSTEM
MICROPROBE RECEIVES $2.9 MILLION INVESTMENT
MICROPROBE RECEIVES FDA CLEARANCE TO MARKET FIRST MICROBIAL IDENTIFICATION SYSTEM FOR VAGINITIS
MICROPROBE RECEIVES PERMISSION TO MARKET ID SYSTEM FOR PERIODONTAL DISEASE-ASSOCIATED ORGANISMS IN 11 COUNTRIES
MICROPROBE AWARDED NIH GRANT FOR ANTIBIOTIC-RESISTANT TUBERCULOSIS DETECTION PROGRAM
BioGenex Awarded U.S. Patent on the Synthesis of Branched Oligomers For Nucleic Acid Labeling and Amplification.
BioGenex awarded United States patent on the synthesis of branched oligomers for nucleic acid labeling and amplification.
Boston Biomedica Awarded U.S. Patent for Use of Pressure Cycling Technology (PCT) in Nucleic Acid Hybridization and Amplification.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters